Company Ceapro Inc. Other OTC
Equities
CRPOF
CA1499071076
Biotechnology & Medical Research
Business Summary
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Active Ingredient Product Technology
100.0
%
| 19 | 100.0 % | 10 | 100.0 % | -48.87% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Germany
49.9
%
| 6 | 31.5 % | 5 | 49.9 % | -19.00% |
United States
47.8
%
| 11 | 58.8 % | 5 | 47.8 % | -58.41% |
Other
1.8
%
| 0 | 0.4 % | 0 | 1.8 % | +153.54% |
Canada
0.3
%
| 0 | 0.2 % | 0 | 0.3 % | -15.21% |
China
0.1
%
| 2 | 9.2 % | 0 | 0.1 % | -99.38% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Gilles Gagnon
CEO | Chief Executive Officer | 70 | 01/07/01 |
Director of Finance/CFO | - | 05/15/05 | |
Mitch Regnier
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
Paul Moquin
CTO | Chief Tech/Sci/R&D Officer | - | 01/18/01 |
Chief Tech/Sci/R&D Officer | - | 01/10/01 | |
General Counsel | - | - | |
Leoni DeJoya
PRN | Corporate Officer/Principal | - | 07/19/07 |
52 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gilles Gagnon
CEO | Chief Executive Officer | 70 | 01/07/01 |
Ulrich Kosciessa
BRD | Director/Board Member | - | 27/15/27 |
William Li
BRD | Director/Board Member | 61 | 20/14/20 |
Ronald Miller
CHM | Chairman | - | 02/22/02 |
Geneviève Foster
BRD | Director/Board Member | - | 19/22/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 78,293,177 | 75,156,073 ( 95.99 %) | 0 | 95.99 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+43.34% | 5.46TCr | |
-5.31% | 3.99TCr | |
+37.52% | 3.88TCr | |
+14.75% | 2.69TCr | |
-12.56% | 2.62TCr | |
-22.45% | 1.88TCr | |
+25.12% | 1.22TCr | |
+0.04% | 1.22TCr | |
+26.04% | 1.19TCr |